IPM 027 Current Status

Dr Annalene Nel, IPM CMO

ASPIRE Team Meeting
MTN Regional Meeting
Westin Cape Town Hotel, Cape Town South Africa
25 October 2014
The Ring Study

IPM 027

Protocol Version 3.0 Amendment 1.0 Dated 12 September 2013

<table>
<thead>
<tr>
<th>Objectives</th>
<th>Long-term Safety and Efficacy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Study design</td>
<td>Double-blind, Randomized (2:1), Placebo-controlled</td>
</tr>
<tr>
<td>Investigational product</td>
<td>Vaginal rings inserted every 4 weeks ± 7 days</td>
</tr>
<tr>
<td>Endpoints</td>
<td>Approx 96 endpoints; 2 year on IP</td>
</tr>
<tr>
<td>Power</td>
<td>81% power to detect 50% treatment effect</td>
</tr>
<tr>
<td>Targeted enrollment</td>
<td>1950 women, ages 18-45</td>
</tr>
<tr>
<td>Sites in Africa</td>
<td>7 IPM research center partners in 2 countries</td>
</tr>
<tr>
<td>Participant follow-up</td>
<td>2 years + 6 weeks following ring discontinuation</td>
</tr>
</tbody>
</table>
Clinical Research Centres

**Madibeng Center for Research**
Brits, South Africa
First enrolled participant – 11 Apr ’12

**Maternal, Adolescent and Child Health (MatCH)**
Edendale, South Africa
First enrolled participant – 26 Apr ’12

**Prevention of HIV/AIDS Project (PHIVA)**
Pinetown, South Africa
First enrolled participant – 23 Apr ’12

**Qhakaza Mbokodo**
Ladysmith, South Africa
First enrolled participant – 16 Apr ’12

**Uganda Virus Research Institute (UVRI)**
Masaka, Uganda
First enrolled participant – 12 Sep ’13

**Desmond Tutu HIV Foundation (DTHF)**
Masiphumelele, South Africa
First enrolled participant – 19 Feb ‘14

**Ndlovu Care Group**
Groblersdal, Limpopo, South Africa
First enrolled participant – 20 Mar ‘14
Key focus

Participants

Community

Research Centres
Key focus - Participants

Recruitment – *Screening stopped*
- Initiated 2 new Research Centres
- Regular calls to review recruitment plans & strategize

Retention – *Downward trend in discontinuation rate*
- Weekly notification of missed / late visits
- Regular calls to review discontinuations & strategize
- Additional rings dispensed
Recruitment

Screened: Enrolled Ratio is 2:1
Snapshot: 23 Oct ’14

681
391
603
361
413
225
896
395
283
161
44
29
54
26

400 Additional
1919 enrolled
31 to enroll
57 in screening
Visit Adherence

IPM 027 average attendance per quarter for ongoing participants

- MCR
- MatCH
- QM
- MRC/UVRI
- Maal
- NCG
- Overall

Average % attendance per quarter for ongoing participants

Q2 - '12 Q3 - '12 Q4 - '12 Q1 - '13 Q2 - '13 Q3 - '13 Q4 - '13 Q1 - '14 Q2 - '14 Q3 - '14
Key focus - Participants

**Adherence - Positive trend in protocol adherence**

- Increase in no of additional rings dispensed
- Weekly notification of missed / late visits
- Monthly participant adherence events
- “Ring out” listings - targeted counselling & adherence events
- Targeted messages on ‘adherence is key’ (e.g. armbands, key rings, t-shirts)
- Blinded objective adherence data shared monthly
- Review counselling source documentation - feedback and training provided
- New face for research centre waiting areas
- Vision boards for communication with participants
% Missed Visits / Quarter

*Note Missed Visits are calculated on retrospective data and may change as participants are discontinued or reach end of product dates.
Key focus

- Participants
- Community
- Research Centres
Key focus – Community Engagement

- Male and Partner events
- Community engagement plans
- Advocacy partners training
- CAB / CAG meetings
- Journalist training
- Stakeholder
- Rumour mitigation
- Wellness days
Key focus

Participants

Community

Research Centres
Key focus - Research Centres

- Team profiling & team building
- Skills workshops
- Weekly calls to review status & support
- Ring Adherence
- Data Quality
- Protocol compliance

Risk Based Monitoring
Next 12 months: Preparing for Success

Adherence – remains key focus
Complete enrolment
Planning for Dec / Jan holiday period
Retention ➔ Women on product for 2 years
Keeping participants & teams passionate
Preparing for success – IPM 032
Inspection readiness
Open-Label Timeline Scenarios

**IPM 032 / MTN-025**
- Both protocols submitted to MCC by 12Sep ’14
- EC / IRB submissions ongoing

**DPV Ring Regulatory Consultations**

**The Ring Study**

**ASPIRE**

**Supporting safety and clinical pharmacology studies**

**Regulatory submissions**

**IPM 032 / MTN-025**
- Expected approval

**IPM 032**

**MTN-025**

**IPM 032 / MTN-025**
- Implementation pending efficacy results & NRA feedback
together Everyone Achieves More....
Thank you .....